Mark Wappett

Reproducible, Quantitative, and Flexible Molecular Subtyping of Clinical DLBCL Samples Using the NanoString nCounter System

Margaret H. Veldman-Jones, Zhongwu Lai, Mark Wappett et al. · Clinical Cancer Research · 2014 · 75 citations

Whole transcriptome profiling of patient-derived xenograft models as a tool to identify both tumor and stromal specific biomarkers

James Bradford, Mark Wappett, Garry Beran et al. · Oncotarget · 2016 · 42 citations · Full text

Pevonedistat (MLN4924): mechanism of cell death induction and therapeutic potential in colorectal cancer

Jennifer S. Ferris, Margarita Espona‐Fiedler, Claudia Hamilton et al. · Cell Death Discovery · 2020 · 38 citations · Full text

RNA-Seq Differentiates Tumour and Host mRNA Expression Changes Induced by Treatment of Human Tumour Xenografts with the VEGFR Tyrosine Kinase Inhibitor Cediranib

James Bradford, Matthew R. Farren, Steve Powell et al. · PLoS ONE · 2013 · 34 citations · Full text

Pathology, Transcriptomics Technology, Pre-clinical Models +23

Enhanced MAPK signaling drives ETS1-mediated induction of miR-29b leading to downregulation of TET1 and changes in epigenetic modifications in a subset of lung SCC

Molly A. Taylor, Mark Wappett, Oona Delpuech et al. · Oncogene · 2016 · 33 citations · Full text